Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.
Vaxcyte, Inc., a San Carlos, Calif.-based biopharmaceutical company, will host a conference call on Monday at 8:00 a.m. ET to present the topline data from its OPUS-1 adult pivotal Phase 3 trial for its 31-valent pneumococcal conjugate vaccine candidate, VAX-31. The trial evaluated the safety, tolerability, and immunogenicity of VAX-31, which is designed to prevent invasive pneumococcal disease and pneumococcal pneumonia.
The conference call can be accessed through a toll-free number for domestic callers or an international conference ID. VAX-31 is being evaluated in both adult and infant clinical programs, while the company also has a 24-valent pneumococcal conjugate vaccine candidate, VAX-24, with Phase 2 clinical results in adults and infants.
Vaxcyte's pipeline includes additional vaccine candidates, such as VAX-XL for expanded pneumococcal coverage, VAX-A1 for Group A Strep prevention in Phase 1 trials, and VAX-GI designed to prevent Shigella. The company utilizes its cell-free protein synthesis platform, XpressCF, licensed from Sutro Biopharma, Inc., for vaccine development.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Vaxcyte to present phase 3 trial data for vaccine candidate investing.com
- Vaxcyte jumps on phase 3 data for pneumonia vaccine VAX-31 seekingalpha.com
